# Biomarker-Targeted Confirmatory Trials

- 标题：靶向生物标志物**验证性试验**
- 重点：验证性试验

# 导入

- The design of confirmatory phase III trials involving predictive biomarkers has a wide range from enrichment design to all-comers design.
	从富集设计到全患群设计，涉及预测性生物标志物的验证性III期（临床）试验的设计范围很广。

## 富集设计(enrichment design)

- The enrichment design only enrolls patients tested positive for the biomarker and is often the most efficient and ethical approach when there is established evidence that treatment benefit is restricted to the biomarker positive group.
	富集设计**仅纳入生物标志物检测阳性的患者**，并且当有既定证据表明治疗获益仅限于生物标志物阳性组时，富集设计通常是最有效和最符合伦理的方法。

- On the other hand, when there is inadequate evidence that treatment benefit is restrictive and no concern for the safety of patients in the biomarker-negative group.
	另一方面，当没有足够的证据表明治疗获益是有限的，并不需去担心生物标志物阴性组患者的安全性。
## 全患群设计(all-comers design)

- an all-comer design that enrolls all patients regardless of their biomarker status will have the advantage of evaluating treatment effect concurrently in the overall population and the biomarker subgroups.
	全患群设计将纳入所有患者，无论生物标志物是否阳性，它具有在总体人群和生物标志物亚组中同时评价治疗效果的优势。

- An all-comer design also offers the opportunity for maximizing the size of patient population, often an important consideration for drug developers.
	全患群设计还提供了最大化患者人群规模的机会，这通常是药物开发人员的重要考虑因素。

# 本章内容

- This chapter is devoted to statistical issues related to all-comer designs. A comprehensive review of related methods for other designs such as enrichment and biomarker-strategy designs can be found in Freidlin and Korn (2014) and Ondra et al. (2016).
	这一章专门讨论与**全患群设计**有关的统计问题。Freidlin和Korn（2014）和Ondra等人（2016）对其他设计（如富集和生物标志物策略设计）的相关方法进行了全面**综述**。